|Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions.|
|Jump to Full Text|
|PMID: 22669736 Owner: NLM Status: MEDLINE|
|BACKGROUND: Assessment of cardiac innervation using single-photon emission computer tomography (SPECT) is less established than planar imaging, but may be more suitable for quantification. Therefore, a volumetric quantification of I-123 MIBG SPECT acquisitions was performed. Reproducibility, the effects of extra cardiac I-123 MIBG uptake and the relation with conventional planar indices were evaluated.
METHODS: 54 patients referred for planar and SPECT I-123 MIBG acquisitions were included. Ellipsoidal or box-shaped volumes of interest were placed on the left ventricle, cardiac lumen, mediastinum, lung and liver. SPECT segmentation was performed twice in all patients. Indices were determined based on the heart-to-mediastinum (HM), myocardial wall-to-mediastinum and myocardial wall-to-lumen regions. HM ratios and washout rates were also determined based on anterior planar images.
RESULTS: Cardiac count densities were highly reproducible (CV 1.5-5.4, ICC 0.96-0.99) and inter-rater variability was low (CV 1.8-6.8, ICC 0.94-0.99). Mediastinal uptake was an important explanatory variable of uptake in the entire heart (early R(2) = 0.36; delayed R(2) =0.43) and myocardial wall (early R(2) = 0.28; delayed R(2) = 0.37). Lung washout was an explanatory variable of organ washout of the heart (heart R(2) = 0.38; myocardial wall R(2) = 0.33). In general, SPECT indices showed moderate-to-good correlations with the planar uptake (PCC 0.497-0.851).
CONCLUSION: By applying a volumetric segmentation method we were able to segment the heart in all patients. SPECT I-123 MIBG quantification was found to be highly reproducible and had a moderate to good correlation with the planar indices.
|Berlinda J van der Veen; Imad Al Younis; Albert de Roos; Marcel P M Stokkel|
Related Documents :
|15878566 - The incidence of implantable cardioverter defibrillator indications in patients admitte...
14610386 - Routine implantation of cardioverter/defibrillator devices in patients aged 75 years an...
8205656 - Electrophysiological laboratory, electrophysiologist-implanted, nonthoracotomy-implanta...
939936 - Clinical efficacy of a truncated exponential decay defibrillator.
24570566 - Surgery for left ventricular pseudoaneurysm: thoracotomy or sternotomy.
22902156 - Recent temporal trends and geographic distribution of cardiac procedures in alberta.
|Type: Journal Article Date: 2012-06-06|
|Title: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology Volume: 19 ISSN: 1532-6551 ISO Abbreviation: J Nucl Cardiol Publication Date: 2012 Aug|
|Created Date: 2012-07-13 Completed Date: 2012-12-07 Revised Date: 2013-07-12|
Medline Journal Info:
|Nlm Unique ID: 9423534 Medline TA: J Nucl Cardiol Country: United States|
|Languages: eng Pagination: 752-62 Citation Subset: IM|
|Department of Nuclear Medicine, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Heart / radionuclide imaging*
Heart Ventricles / pathology
Image Processing, Computer-Assisted / methods*
Iodine Radioisotopes / pharmacology
Mediastinum / pathology
Myocardium / pathology
Radiopharmaceuticals / pharmacokinetics
Reproducibility of Results
Tomography, Emission-Computed, Single-Photon / methods*
|0/Iodine Radioisotopes; 0/Radiopharmaceuticals; 77679-27-7/3-Iodobenzylguanidine|
Journal ID (nlm-ta): J Nucl Cardiol
Journal ID (iso-abbrev): J Nucl Cardiol
Publisher: Springer-Verlag, New York
© The Author(s) 2012
Received Day: 13 Month: 10 Year: 2011
Accepted Day: 18 Month: 2 Year: 2012
Electronic publication date: Day: 6 Month: 6 Year: 2012
pmc-release publication date: Day: 6 Month: 6 Year: 2012
Print publication date: Month: 8 Year: 2012
Volume: 19 Issue: 4
First Page: 752 Last Page: 762
PubMed Id: 22669736
Publisher Id: 9539
|Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions|
|Berlinda J. van der Veen, MSc1||
Address: 0031-715263475 0031-7157266751 firstname.lastname@example.org
|Imad Al Younis, MD1|
|Albert de Roos, MD, PhD2|
|Marcel P. M. Stokkel, MD, PhD3|
1Department of Nuclear Medicine, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
2Department of and Radiology, Leiden University Medical Centre, Leiden, The Netherlands
3Department of Nuclear Medicine, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Innervation imaging with radioiodinated meta-iodobenzylguanidine (I-123 MIBG) is the most widely used imaging technique to evaluate sympathetic nerve activity in cardiac diseases. The resemblance of MIBG to norepinephrine with respect to the molecular structure, synaptic uptake and intracellular storage makes it a suitable tracer to study sympathetic nervous activity.1-4
In general, the in-vivo visualization of cardiac innervation is evaluated on planar anterior images, which are acquired early and 3 to 5 hours after tracer injection. For quantification, myocardial and mediastinal regions of interest (ROIs) are drawn on anterior planar images, of which mediastinal ROI is thought to represent the non-specific I-123 MIBG uptake in soft tissue.5 Information on the distribution of neurons and function of the (re-)uptake-1 pathway is provided by the heart-to-mediastinum (HM) ratio, while the washout rate (WOR) provides information on the sympathetic drive. Both indices are commonly applied in I-123 MIBG imaging and the inter- and intraobserver variability of the HM ratio are considered low.6,7
Though planar imaging is widely used, quantification based on these acquisitions has important limitations. Precise quantification of myocardial counts is often complicated due to superimposition of adjacent organs onto the cardiac region. Furthermore, planar images do not contain three-dimensional information, making it difficult to assess regional innervation abnormalities.8,9 Single-photon emission computer tomography (SPECT) is known to overcome these problems. Still, the quantification of global cardiac innervation using SPECT is less established than planar I-123 MIBG imaging.
At present, SPECT imaging is considered informative in diseases like ischaemic heart disease, ventricular arrhythmias and diabetes mellitus were the cardiac innervation is affected in a heterogeneous manner.9 Consequently, this technique is increasingly used to assess the regional I-123 MIBG uptake.6,8,10-13 Using SPECT, it is possible to distinguish between myocardial wall, left ventricular lumen and surrounding organs. The ability to precisely localize these organs may suggest that SPECT acquisitions are also more suitable for the quantification of global innervation. To explore this hypothesis, we applied a simple volumetric quantification method on cardiac I-123 MIBG SPECT acquisitions. Global uptake in the heart, myocardial wall, ventricular lumen and surrounding organs were determined in clinical patient groups. Based on this data we studied reproducibility of SPECT segmentation, the effect of extra cardiac I-123 MIBG uptake and the relation between SPECT or the conventional planar indices.
The included population consisted of patients referred for I-123 MIBG acquisition prior to placement of a (biventricular) cardiac device (ICD) (group ICD, n = 28), to distinguish between neurodegenerative diseases (group NDD, n = 11), or after radiotherapy-chemotherapy (group RCT, n = 15). Since these groups all contain clinical patients, none of them can be considered a normal reference population. Still, the selection of these three populations ensures the inclusion of patients with a low cardiac I-123 MIBG uptake and a relatively normal I-123 MIBG uptake. All patients were referred for both planar and SPECT acquisitions in the period from November 2008 to March 2011 as part of their clinical work-up. Characteristics of the patient populations are provided in Table 1.
Patients were instructed to abstain from medication that could influence I-123 MIBG distribution (mainly antihypertensive drugs and tricyclic-antidepressants).5 Prior to I-123 MIBG administration patients underwent thyroid blocking by NaI droplets or KI capsules to prevent thyroid uptake of free radioiodine. An average dose of 185 MBq I-123 MIBG was slowly infused in 2 to 3 minutes. Anterior planar and SPECT images were obtained approximately 15 minutes (early) and 4 hours (delayed) after the injection. Anterior planar images were acquired using a dual-detector gamma camera (Toshiba, CGA 7200, Tokyo, Japan) equipped with a low energy high-resolution collimator (energy range up to 170 keV). Images were collected for 10 minutes with a 20% energy window centred on the 159 keV photo peak. The SPECT images were acquired with similar camera settings over 180° from right anterior oblique to left posterior oblique. Projections were made every 4° at 35 seconds per angle using a 128 × 128 matrix (zoom factor 1.5). SPECT data was reconstructed by ordered subset expectation maximization with 2 iterations and 10 subsets using a Gaussian post-processing filter (FWHM = 15 mm). No other filter or attenuation correction was applied.
On the early and late images ROIs were defined by an experienced nuclear medicine technologist. The heart ROI was manually drawn to follow the external contours of the heart, thus including the myocardium and the left ventricular lumen. The apices of the lung and the mid-mediastinal line were used as anatomical landmarks for placement of a rectangular mediastinal ROI. The mean counts per pixel were determined in the early (e) and delayed (d) acquisitions for each ROI and corrected for decay. The early and delayed HM ratios were calculated as follows;
According to the proposal for cardiac I-123 MIBG guidelines,5 WOR is defined as;
SPECT image analysis was performed on a Syngo-MI workstation (Siemens Medical Solutions, USA). In a mid-ventricular short axis (SA) view an ellipsoid was placed to contain the entire heart. In the horizontal-long axis (HLA) and vertical-long axis (VLA) views the placement of this ellipsoid was evaluated and adjusted when needed to enclose the base and apex. A second ellipsoid was positioned to contain the left ventricular lumen. Based on this information, three-dimensional volumes of interest (VOIs) are automatically created for the heart and lumen. The activity in the myocardial wall was defined as ‘left ventricular counts minus lumen counts’. A box-shaped mediastinal VOI was placed conform the planar methodology. Uptake ratios and WOR were determined by applying the aforementioned formulas to three VOI combinations; HM, myocardial wall-to-mediastinum (MM) and myocardial wall-to-lumen (ML) regions. These values were compared to the planar indices to determine the discriminatory value of the SPECT indices in the patient populations.
The quantitative values determined on planar images are prone to count changes in the adjacent organs. To study the effects of I-123 MIBG uptake in adjacent organs in SPECT quantification, box-shaped VOIs were placed in centre of the liver and right lung. All box-shaped VOIs were between 10 and 15 cm3. For each VOI the size, uptake and washout were determined. The organ-specific washout was defined as;
Reliability is an important aspect when manual segmentation is performed to assess SPECT data. Therefore, all acquisitions were segmented twice by the same experienced observer to evaluate the test-retest variability. The second segmentation was performed 2 weeks after the first segmentation to reduce observer bias. The manual SPECT-based segmentation was also performed by a second experienced observer to allow assessment of the inter-rater variability.
Statistical analyses were executed using the SPSS v16.0 software (SPSS inc. Chicago, USA). All continuous variables are expressed as ‘mean ± standard deviation’, and categorical data was expressed as frequencies and/or percentages. Continues variables were assessed for their distribution with the Shapiro-Wilk test.
Reliability can be described by a number of different statistical techniques. It is often considered a multi-factorial problem that is open to interpretation and is therefore assessed by multiple measures.14-16 In this study, test-retest and inter-rater reliability (i.e. reproducibility) were evaluated by the coefficient of variation (CV) and the intraclass correlation coefficient.
In addition to reproducibility of the segmentation factors like VOI size and I-123 MIBG uptake in surrounding organs may also influence quantification of counts within the heart. If a dependency exists between measured counts and either the size of the VOI or uptake in surrounding organs, the measurements are also considered less reliable. The relationship between VOI size and measured counts is determined by Pearson correlation coefficients (PCC). Stepwise multivariable regression analysis was used to determine the effects of I-123 MIBG uptake in the surrounding organs on the cardiac values. Regression analysis is described by the coefficient (B), standard error (se) and the total model fit (R2). The global SPECT uptake ratios and WORs were compared to the widely used planar indices. Correlations between the planar and the SPECT values were expressed by Pearson correlation or Spearmann’s rank correlation, when appropriate.
In all acquisitions the segmentation was performed twice to assess the test-retest reliability. Size differences between the first and the second segmentations were found for all VOIs, as could be expected. The reproducibility of the box-shaped VOI size was considered relatively low (ICC ranging from −0.17 to 0.03 and CV ranging from 12.2% to 18.4%). In general, the elliptical cardiac VOIs (i.e. heart and lumen) had high ICC values indicating a good correlation, but also relatively high CV values suggesting high levels of variability between the segmentations. The size differences and the corresponding ICC or CV values are provided in Table 2a.
A low reproducibility of VOI size could result in poor reliability of the measured count densities. Nonetheless, the variability in count densities derived from the box-shaped VOIs was moderate, suggesting that the count densities obtained by the box-shaped VOI can be reliable. The cardiac VOIs provide highly reliable count densities in the test-retest evaluation (see Table 2b). The ICCs and CVs of the uptake ratios determined based on the three VOI combinations (HM, MM and ML) are provided in Table 2c. The inter-rater variability of the count densities for the cardiac VOIs was also considered low, as can be seen in Table 3. Both the CV and the ICC suggest a high degree of consistency in the values produced by the two raters. The variation among the uptake ratios is higher, as was also demonstrated in the test-rest analysis.
When the total population is subdivided into the three patient groups, the test-retest ICC for the heart counts is 0.99 for each of the groups and the ICC for the ventricular counts VOI ranges from 0.90 to 0.98. The inter-rater ICC for the heart counts ranges from 0.97 to 0.99 and for the ventricular lumen from 0.88 to 0.99. So, both in the affected and near-normal populations SPECT segmentation of the heart can be considered reproducible.
The results of the test-retest analysis already suggest that there is no clear relationship between the VOI size and the count densities. Mean VOI sizes for all measurements are provided in Table 2a. When assessing the correlation between size and counts in all segmentations, no significant correlations were found in both early and delayed SPECT for liver (early PCC = 0.179, P = .066; delayed PCC = −0.015, P = .876), lung (early PCC = 0.131, P = .182; delayed PCC = 0.155, P = .112), heart (early PCC = −0.123, P = .209; delayed PCC = −0.143, P = .144) and mediastinal VOIs (early PCC = 0.030, P = .759; delayed PCC = −0.063, P = .524). Only for the lumen VOI moderate correlations were found in both early and delayed segmentations (early PCC = −0.344, P < .001; delayed PCC = −0.227, P = .020) suggesting a relationship between VOI size and measured counts.
The effect of I-123 MIBG uptake in the surrounding organs was evaluated by multivariable regression analysis. The mediastinal uptake was an independent predictor of uptake within the entire heart (early B = 2.06, se = 0.38, R2 = 0.36; delayed B = 2.74, se = 0.448, R2 = 0.43) and in the myocardial wall (early B = 0.96, se = 0.22, R2 = 0.28; delayed B = 1.27, se = 0.248, R2 = 0.37). The lung washout was found to be an important explanatory variable of the organ washout in the entire heart (B = 0.58, se = 0.10, R2 = 0.38) and the myocardial wall (B = 0.69, se = 0.14, R2 = 0.33). For both cardiac uptake and washout, changes in liver uptake were not considered an important factor. The luminal count densities, although not included in the multivariate analysis, did show a strong relation to the uptake and washout in the heart or myocardial wall (Figure 3).
The values for the planar and SPECT indices for the three different populations are provided in Table 4, as are the correlation between the SPECT and the planar indices. Especially the cardiac uptake ratios determined based on the SPECT data had a good correlation with the planar uptake values, as can be seen in Figure 4. The method using the ML ratio had the lowest regression coefficients, whereas the HM and MM had a moderate-to-good relationship with the planar indices. Using these latter two methods, it was also possible to discriminate between the three clinical patient populations (see Table 4).
In this study, a simple volumetric-based segmentation of I-123 MIBG SPECT data was introduced to determine global uptake and washout in the entire heart and myocardial wall. Both the test-retest and the inter-rater reproducibility of the measured cardiac count densities were high, despite the low reproducibility of the VOI sizes. In both the affected and the near-normal populations SPECT segmentation of the heart can be performed and was found to be reproducible. The correlations between the widely used planar and SPECT indices was high for the uptake ratios determined based on the HM and MM regions. The differences between the three clinical patient populations were most profound when using the HM SPECT indices, which may suggest that this method has the best discriminatory value.
The extent to which external factors influence a measurement can be just as important for the clinical value of a technique as the reproducibility or the discriminatory value. Verberne et al.17 demonstrated that cardiac organ washout on planar images can be explained by a model containing mediastinum and lung washout. This implies that changes in myocardial count densities overtime are, to some extent, related to count changes in the surrounding organs.
Since cardiac segmentation can be performed more precisely on SPECT images due to the three-dimensional information content, it was anticipated that cardiac count densities determined on SPECT images were less prone to influences from surrounding organs. The results of this study suggest that mediastinal uptake was an important explanatory variable of cardiac uptake on both early and delayed images. Lung washout, on the other hand, was an independent predictor of the cardiac washout. Even though, the inclusion of mediastinal and lung counts into the cardiac VOI is limited when applying SPECT segmentation; these count densities do seem to correlate with the cardiac uptake and washout measures. Whether these effects are caused by technical problems in the segmentation, or reflect a true relation in the innervation processes within these organs remains unclear.
Liver uptake or washout had a smaller impact on quantification of cardiac counts, as was shown by both the study of Verberne et al17 and our study. Still, it is described that liver uptake has to be reckoned with when visually assessing I-123 MIBG SPECT images.13,18 Most often, uptake in the liver causes areas of reduced myocardial count densities, especially in inferior wall. In severe cases, the liver will superimpose on the myocardial wall making the entire inferior wall non-assessable.
In advance, it was hypothesized that SPECT imaging could also be more suitable for global quantification as it can distinguish between myocardial wall, ventricular lumen and surrounding organs. When using separate VOIs to describe the myocardial wall and lumen, it is possible to use the cardiac lumen as non-specific uptake measure which can be calibrated using a blood sample. This methodology was previously described by Somsen et al.19 Their study concluded that this is an accurate method to assess myocardial I-123 MIBG uptake.
The results of our study (Figure 3) demonstrate a strong positive relationship between the cardiac and the lumen count densities. This correlation is most likely the result of the spillover effect from the myocardial wall, and probably does not reflect a true relation between myocardial counts and the non-specific I-123 MIBG uptake. Additionally, the gathered experience suggests that lumen VOIs are more difficult to position than heart VOIs, especially in patients with small heart sizes or severely reduced cardiac uptake. These observations are supported by the reproducibility analysis, in which variability of lumen counts is higher than the variability of cardiac counts. Furthermore, a moderate correlation between the VOI size and the count densities was found for the lumen, suggesting that lumen counts are partly dependent on VOI size. All these findings suggest that lumen-based quantification of non-specific uptake may be less reliable, than for instance the mediastinal counts. Additionally, a recent study demonstrated in planar images that cardiac and mediastinal count densities are unrelated to changes in vascular I-123 MIBG activity, making a blood pool correction somewhat redundant.20
Uptake ratios as well as washout determined by the MM or HM regions showed a good relationship with the planar indices (Figure 4). The measurements based on the HM regions were considered to be more reproducible than the MM measures, and had a better discriminatory value. Still, more research has to be performed to establish the clinical value of both of these SPECT-based quantification methods.
The majority of the studies visually score cardiac uptake based on either the SA, HLA and VLA views or polarmap display.6,8,10-13,22-24 Automated evaluation or comparisons to a normal database are possible when polarmaps are used. All these methods rely on the basic principle that segmental uptake is scaled to the maximum count density within the heart. However, I-123 MIBG uptake can be abnormal throughout the myocardium creating a false representation of cardiac uptake. Additionally, false positive washout defects can be induced when discrepancies in delineation or orientation between the early and the delayed images are present. Thus, it is important to relate visual or automated scoring to count-based indices such as the HM ratio.5
At present, there are only a few studies that describe count-based indices derived from I-123 MIBG SPECT data. Druschky et al21 placed 33 small square ROIs in six SA slices to assess global and regional myocardial uptake. Results were expressed as percentage of the maximum ROI, and were used to calculate an inhomogeneity index. Since counts in each ROI are scaled to the maximum uptake, one expects that the scaling problem can arise in patients with overall reduced I-123 MIBG uptake. However, the idea of an inhomogeneity index is probably more suitable to described I-123 MIBG abnormalities in SPECT data, because there is no need to scale the data.
Somsen et al19 used single- and multi-slice SPECT data in which cardiac counts were related to either lumen or organ uptake. Their findings indicate that the single-slice SPECT method had a poor reproducibility, making it less suitable for global quantification. The multi-slice method, in which the entire cardiac volume is segmented, had a high reproducibility with CVs of <5%. The results found for the multi-slice method are comparable to the results found in our study.
The regional assessment of cardiac innervation using SPECT is less established than planar I-123 MIBG imaging. In general, SPECT imaging is advisable in diseases were cardiac innervation is affected in a heterogeneous manner. There are, at present, a few clinical indications described for SPECT imaging which include ischaemic heart disease, ventricular arrhythmias and diabetes mellitus.9
The areas of sympathetic denervation often exceed beyond that of the perfusion defects, because sympathetic neurons are considered to be more sensitive to ischaemic events than cardiac myocytes. Furthermore, it is thought that chronic repetitive ischaemia may induce long-term sympathetic nerve dysfunction.25 These mechanisms also ensure that in the early stages of coronary artery disease or during frequent vasospastic events, sympathetic neurons can be affected without the presence of obvious perfusion defects.11,22,26 This heterogenic cardiac sympathetic innervation, in otherwise viable myocardium, is thought to be the source of electrical instability which is associated with the development of ventricular arrhythmias.12,27 The role of SPECT I-123 MIBG imaging in ischaemic heart disease and ventricular arrhythmias is therefore mainly focused on describing the regional sympathetic innervation status and detecting areas with perfusion/innervation mismatch.10,28 Cardiac autonomic neuropathy (CAN) in patients with diabetes mellitus, on the other hand, is associated with regional hyperactivity of the sympathetic nervous system, resulting in an electrical instability.8,29 It is recognized that planar I-123 MIBG imaging is useful to detect CAN and provide prognostic information on future cardiac events.30-32 However, planar indices are less sensitive in detecting small regional abnormalities which are often associated with diabetic neuropathy. Therefore, it was suggested by Hattori et al8 that I-123 MIBG SPECT imaging should be used to detect CAN. Still, the additive role of SPECT imaging in diabetes needs to be established.
In this study, a straightforward volumetric technique was introduced that is able to provide reproducible global I-123 MIBG parameters. The initial results indicate that it is possible to distinguish between different patient populations using these SPECT indices, and that these indices relate to the planar measures. Still, this study does not provide a validation of this quantitative method. Such a validation will require the comparison of the new SPECT-based method to a golden standard. At present, there are no measures that can serve as a true golden standard, only the prognosis of the patient can be used as such. The only other imaging technique that is able to directly assess cardiac sympathetic innervation is C-11 meta-hydroxyephedrine (HED) positron emission tomography (PET).33 This technique is, however, only available in a limited number of centres and is not yet considered to be standard clinical practice. Accordingly, more research has to be performed to establish the value of I-123 MIBG SPECT imaging over planar imaging in specific patient populations.
By applying a simple volumetric segmentation method we were able determine global uptake and washout in the entire heart or myocardial wall in all patients. In general I-123 MIBG SPECT quantification was found to be highly reproducible, reliable and had a moderate-to-good correlation with the planar indices. Still, the additive value of I-123 MIBG SPECT quantification over planar imaging has to be established in specific patient populations.
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
|1..||Carrio I. Cardiac neurotransmission imagingJ Nucl MedYear: 2001421062107611438630|
|2..||Ji SY,Travin MI. Radionuclide imaging of cardiac autonomic innervationJ Nucl CardiolYear: 20101765566610.1007/s12350-010-9239-x20454877|
|3..||Henneman MM,Bengel FM,Wall EE,Knuuti J,Bax JJ. Cardiac neuronal imaging: application in the evaluation of cardiac diseaseJ Nucl CardiolYear: 20081544245510.1016/j.nuclcard.2008.02.02318513651|
|4..||Yamashina S,Yamazaki J. Neuronal imaging using SPECTEur J Nucl Med Mol ImagingYear: 20073493995010.1007/s00259-006-0359-017268772|
|5..||Flotats A,Carrio I,Agostini D,et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear CardiologyEur J Nucl Med Mol ImagingYear: 2010371802181210.1007/s00259-010-1491-420577740|
|6..||Somsen GA,Verberne HJ,Fleury E,Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studiesJ Nucl CardiolYear: 20041112613310.1016/j.nuclcard.2003.10.01015052243|
|7..||Muxi A,Paredes P,Navales I,et al. Diagnostic cutoff points for (1)(2)(3)I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson’s diseaseEur J Nucl Med Mol ImagingYear: 2011381139114610.1007/s00259-011-1754-821373765|
|8..||Hattori N,Tamaki N,Hayashi T,et al. Regional abnormality of iodine-123-MIBG in diabetic heartsJ Nucl MedYear: 199637198519908970519|
|9..||Flotats A,Carrio I. Cardiac neurotransmission SPECT imagingJ Nucl CardiolYear: 20041158760210.1016/j.nuclcard.2004.07.00715472644|
|10..||Boogers MJ,Borleffs CJ,Henneman MM,et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patientsJ Am Coll CardiolYear: 2010552769277710.1016/j.jacc.2009.12.06620538172|
|11..||Matsunari I,Aoki H,Nomura Y,et al. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunctionCirc Cardiovasc ImagingYear: 2010359560310.1161/CIRCIMAGING.109.92053820534790|
|12..||Simoes MV,Barthel P,Matsunari I,et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarctionEur Heart JYear: 20042555155710.1016/j.ehj.2004.02.01615120051|
|13..||Tsuchimochi S,Tamaki N,Tadamura E,et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imagingJ Nucl MedYear: 1995369699747769454|
|14..||Chinn S. Statistics in respiratory medicine. 2. Repeatability and method comparisonThoraxYear: 19914645445610.1136/thx.46.6.4541858087|
|15..||Bruton A,Conway JH,Holgate ST. Reliability: What is it, and how is it measured?PhysiotherapyYear: 200086949910.1016/S0031-9406(05)61211-4|
|16..||McGraw KO,Wong SP. Forming inferences about some intraclass correlation coefficientsPsychol MethodsYear: 19961304610.1037/1082-989X.1.1.30|
|17..||Verberne HJ,Somsen GA,Povinec P,Eck-Smit BL,Jacobson AF. Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washoutEur J Nucl Med Mol ImagingYear: 2009361322132810.1007/s00259-009-1093-119259662|
|18..||Gill JS,Hunter GJ,Gane G,Camm AJ. Heterogeneity of the human myocardial sympathetic innervation: In vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphyAm Heart JYear: 199312639039810.1016/0002-8703(93)91056-K8338010|
|19..||Somsen GA,Borm JJ,Milliano PA,Vlies B,Dubois EA,Royen EA. Quantitation of myocardial iodine-123 MIBG uptake in SPET studies: A new approach using the left ventricular cavity and a blood sample as a referenceEur J Nucl MedYear: 1995221149115410.1007/BF008005978542899|
|20..||Verberne HJ,Verschure DO,Somsen GA,Eck-Smit BL,Jacobson AF. Vascular time-activity variation in patients undergoing (1)(2)(3)I-MIBG myocardial scintigraphy: Implications for quantification of cardiac and mediastinal uptakeEur J Nucl Med Mol ImagingYear: 2011381132113810.1007/s00259-011-1783-321461736|
|21..||Druschky A,Hilz MJ,Platsch G,et al. Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECTJ Neurol SciYear: 200017531210.1016/S0022-510X(00)00279-310785250|
|22..||Simula S,Vanninen E,Viitanen L,et al. Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary artery diseaseJ Nucl MedYear: 2002431711801695|
|23..||Wakabayashi T,Nakata T,Hashimoto A,et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac deathJ Nucl MedYear: 2001421757176711752070|
|24..||Yukinaka M,Nomura M,Ito S,Nakaya Y. Mismatch between myocardial accumulation of 123I-MIBG and 99mTc-MIBI and late ventricular potentials in patients after myocardial infarction: Association with the development of ventricular arrhythmiasAm Heart JYear: 199813685986710.1016/S0002-8703(98)70132-29812082|
|25..||Fallavollita JA,Canty JM Jr. Dysinnervated but viable myocardium in ischemic heart diseaseJ Nucl CardiolYear: 2010171107111510.1007/s12350-010-9292-520857351|
|26..||Sakata K,Iida K,Kudo M,Yoshida H,Dog O. Prognostic value of I-123 metaiodobenzylguanidine imaging in vasospastic angina without significant coronary stenosisCirc JYear: 20056917117610.1253/circj.69.17115671608|
|27..||Chen LS,Zhou S,Fishbein MC,Chen PS. New perspectives on the role of autonomic nervous system in the genesis of arrhythmiasJ Cardiovasc ElectrophysiolYear: 20071812312710.1111/j.1540-8167.2006.00590.x16911576|
|28..||Nishisato K,Hashimoto A,Nakata T,et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDsJ Nucl MedYear: 2010511241124910.2967/jnumed.110.07497120679471|
|29..||Stevens MJ,Raffel DM,Allman KC,et al. Cardiac sympathetic dysinnervation in diabetes: Implications for enhanced cardiovascular riskCirculationYear: 19989896196810.1161/01.CIR.98.10.9619737515|
|30..||Nagamachi S,Fujita S,Nishii R,et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitusJ Nucl CardiolYear: 200613344210.1016/j.nuclcard.2005.11.00916464715|
|31..||Scholte AJ,Schuijf JD,Delgado V,et al. Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variabilityEur J Nucl Med Mol ImagingYear: 2010371698170510.1007/s00259-010-1442-020411258|
|32..||Vinik AI,Ziegler D. Diabetic cardiovascular autonomic neuropathyCirculationYear: 200711538739710.1161/CIRCULATIONAHA.106.63494917242296|
|33..||Bengel FM,Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imagingJ Nucl CardiolYear: 20041160361610.1016/j.nuclcard.2004.06.13315472645|
|ICD (n = 28)||NDD (n = 11)||RCT (n = 15)||P value‡|
|Age (years)||70 ± 6.1||64 ± 12.9||50 ± 10.0||<.001|
|Gender (% male)||20 (71%)||10 (91%)||0||<.001|
|Relevant medical history|
|Autonomic dysfunction||0||9 (81%)||0||<.001|
|Hypokinesia/rigidity||0||5 (45%)||1 (7%)||<.001|
|Diabetes Mellitus||3 (11%)||2 (18%)||1 (7%)||.650|
|Hypertension||12 (43%)||0||2 (13%)||.010|
|Proven CAD||13 (46%)||1 (9%)||0||<.001|
|Heart failure||28 (100%)||0||0||<.001|
|Ventricular arrhythmia||18 (64%)||0||1 (7%)||<.001|
|(Biventricular) ICD||6 (21%)||0||0||<.001|
‡Chi-square or ANOVA tests of the difference in distribution of various factors.
CAD, Coronary artery disease; ICD, implantable cardiac device.
Test-retest reproducibility of (a) VOI size, (b) count densities and (c) uptake ratios
|Liver||13.1 ± 1.3||2.52 ± 1.6||13.7||−0.14||−0.40–0.14|
|Lung||13.0 ± 1.3||2.32 ± 1.5||12.5||−0.09||−0.36–0.19|
|Mediastinum||12.7 ± 1.5||2.32 ± 1.7||18.4||0.00||−0.27–0.28|
|Heart||522.0 ± 237.5||77.2 ± 76.0||10.5||0.90||0.84–0.94|
|Lumen||10.4 ± 6.9||4.38 ± 4.7||29.8||0.65||0.46–0.78|
|Liver||13.2 ± 1.3||2.27 ± 1.7||12.2||−0.13||−0.39–0.15|
|Lung||13.3 ± 1.3||2.58 ± 1.8||13.7||−0.17||−0.43–0.11|
|Mediastinum||12.7 ± 1.5||2.39 ± 1.8||13.3||0.03||−0.25–0.29|
|Heart||519.0 ± 232.2||83.3 ± 107.1||11.5||0.84||0.75–0.91|
|Lumen||10.4 ± 6.9||4.03 ± 4.4||27.6||0.70||0.52–0.81|
|Liver||28.0 ± 7.7||4.14 ± 3.6||10.4||0.79||0.63–0.87|
|Lung||12.8 ± 3.6||0.94 ± 0.9||5.2||0.93||0.88–0.96|
|Mediastinum||4.8 ± 1.3||1.25 ± 1.0||18.4||0.47||0.20–0.66|
|Heart||9.3 ± 3.6||0.20 ± 0.2||1.5||0.99||0.99–1.00|
|Lumen||5.0 ± 1.7||0.33 ± 0.3||4.7||0.96||0.93–0.98|
|Liver||26.6 ± 9.0||3.03 ± 2.5||8.1||0.91||0.81–0.95|
|Lung||10.5 ± 3.0||0.69 ± 0.6||4.6||0.95||0.91–0.97|
|Mediastinum||4.1 ± 1.0||0.50 ± 0.4||8.7||0.84||0.72–0.90|
|Heart||8.2 ± 4.4||0.23 ± 0.2||1.9||0.99||0.99–1.0|
|Lumen||4.4 ± 2.2||0.34 ± 0.3||5.4||0.97||0.95–0.99|
|HM ratio||1.92 ± 0.4||0.48 ± 0.3||17.8||0.37||0.09–0.59|
|MM ratio||0.86 ± 0.3||0.25 ± 0.2||20.1||0.57||0.23–0.77|
|ML ratio||0.82 ± 0.2||0.13 ± 0.2||11.2||0.60||0.37–0.75|
|HM ratio||1.98 ± 0.7||0.26 ± 0.2||9.4||0.90||0.82–0.95|
|MM ratio||0.89 ± 0.4||0.15 ± 0.1||12.0||0.89||0.81–0.93|
|ML ratio||0.81 ± 0.2||0.14 ± 0.1||12.5||0.61||0.40–0.76|
†One sample T test of the absolute differences between the two measurements, all differences were P < .001.
|Mediastinum||4.2 ± 0.9||0.73 ± 0.5||12.2||0.63||0.25–0.81|
|Heart||9.1 ± 3.5||0.35 ± 0.3||2.7||0.99||0.98–1.00|
|Lumen||4.8 ± 1.7||0.46 ± 0.3||6.7||0.94||0.89–0.97|
|HM ratio||2.17 ± 0.6||0.34 ± 0.3||11.0||0.80||0.57–0.90|
|MM ratio||1.01 ± 0.4||0.20 ± 0.2||14.0||0.77||0.58–0.87|
|ML ratio||0.87 ± 0.3||0.19 ± 0.1||14.9||0.52||0.29–0.69|
|Mediastinum||3.9 ± 1.0||0.42 ± 0.3||13.4||0.66||0.30–0.82|
|Heart||8.1 ± 4.3||0.21 ± 0.2||1.8||0.99||0.99–1.00|
|Lumen||4.4 ± 2.2||0.74 ± 0.6||6.8||0.97||0.94–0.98|
|HM ratio||2.08 ± 0.9||0.43 ± 0.5||14.6||0.75||0.52–0.87|
|MM ratio||0.95 ± 0.5||0.23 ± 0.3||17.2||0.74||0.56–0.84|
|ML ratio||0.84 ± 0.2||0.20 ± 0.2||17.3||0.51||0.28–0.69|
†One sample T test of the absolute differences between the two measurements, all differences were P < 0.001.
Relation between planar and SPECT indices
|Correlations†||Mean values for clinical populations‡|
|PCC†||P value||ICD||NDD||RCT||P value|
|Planar HM||–||1.53 ± 0.3||1.44 ± 0.3||1.71 ± 0.2||.024|
|SPECT HM||0.795||<.001||1.95 ± 0.5||1.70 ± 0.8||2.52 ± 0.3||.001|
|SPECT MM||0.771||<.001||0.91 ± 0.3||0.73 ± 0.5||1.20 ± 0.2||.006|
|SPECT ML||0.578||<.001||0.87 ± 0.2||0.69 ± 0.3||0.93 ± 0.2||.011|
|Planar HM||–||1.40 ± 0.2||1.38 ± 0.4||1.75 ± 0.2||<.001|
|SPECT HM||0.851||<.001||1.69 ± 0.6||1.63 ± 1.1||2.54 ± 0.3||<.001|
|SPECT MM||0.842||<.001||0.79 ± 0.3||0.71 ± 0.5||1.22 ± 0.2||.001|
|SPECT ML||0.497||<.001||0.85 ± 0.2||0.74 ± 0.3||0.92 ± 0.2||.139|
|Planar HM||–||0.49 ± 0.38||0.48 ± 0.35||0.15 ± 0.13||<.001|
|SPECT HM||0.706||<.001||0.41 ± 0.65||0.97 ± 1.32||0.04 ± 0.32||.002|
|SPECT MM||0.359||.010||−0.71 ± 2.47||0.10 ± 0.56||1.38 ± 4.30||.044|
|SPECT ML||−0.145||.315||0.18 ± 2.06||−0.65 ± 1.90||1.56 ± 2.40||.163|
HM, Heart-to-mediastinum ratio; MM, myocardial wall-to-mediastinum ratio; ML, myocardial wall-to-lumen ratio.
†Pearson correlation analysis or Spearman’s rank correlation between the planar and the SPECT for uptake and washout indices.
‡Anova or Kruskal-Wallis analysis to determine the difference between the mean values.
Keywords: Keywords I-123 meta-iodobenzylguanidine, myocardial innervation, SPECT, quantitative analysis.
Previous Document: Infraareolar access for thoracoscopic sympathectomy to treat primary hyperhidrosis.
Next Document: Data Quality of Unsupervised Endothelial Cell Counting vs. Reading Centre Analysis in Multicentric C...